Fortitude Advisory Group’s Novavax NVAX Stock Holding History

Fortitude Advisory Group’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-47	Closed	-$3K	–	913
2022 Q1	$3K	Hold	47	–	–	﹤0.01%	1278
2021 Q4	$7K	Buy	+47	New	+$8.08K	﹤0.01%	1132

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fortitude Advisory Group's NVAX Position: Q2 2022 in Review

Fortitude Advisory Group sold out of Novavax (NVAX) in Q2 2022, closing a stake of 47 shares — an estimated $3K sold.

Fortitude Advisory Group first reported a position in NVAX in Q4 2021 and held it in 2 quarters. The position peaked at $7K in Q4 2021. 325 funds tracked by Wall St. Rank hold NVAX as of Q2 2022.

Fortitude Advisory Group reported no remaining Novavax position as of Q2 2022 after selling out during the quarter.
Fortitude Advisory Group sold 47 Novavax shares in Q2 2022, an estimated $3K.
Fortitude Advisory Group first reported a position in Novavax in Q4 2021 and held it in 2 quarters.
Fortitude Advisory Group's Novavax position peaked at $7K in Q4 2021.
325 funds tracked by Wall St. Rank held Novavax as of Q2 2022.

Based on Fortitude Advisory Group's 13F filing for Q2 2022, filed 16 Aug 2022.